Exclusive: Connect Biopharma reports a PhII fail for Zeposia challenger, and execs appear ready to punt

Connect Biopharma is attempting to play catch-up to bigger names in the S1P modulator race, such as Bristol Myers Squibb and Pfizer, now that the latter has scooped up Arena. But Connect’s Phase II study evaluating the program in ulcerative colitis did not achieve its primary goal, leaving the biotech searching for a partner to take on development costs.